Who owns KEZAR LIFE SCIENCES INC?
- CUSIP Number: 49372l209
Tip: Access positions for across all investors
Analyze quarterly positions in Kezar Life Sciences with up to 7 years of data, all consolidated into one spreadsheet
Download as csv
Download as Excel
Top investors of Kezar Life Sciences stock
Who bought or sold KEZAR LIFE SCIENCES INC this quarter?
| Fund or Company Name | Shares Held | Valued At | Change in Shares | As Of | Actions |
|---|---|---|---|---|---|
| BML Capital Management | 721k | $5.3M | 0% | Mar 2026 |
|
| Suvretta Capital Management | 717k | $5.3M | 0% | Mar 2026 |
|
| Tang Capital Management | 664k | $4.9M | 0% | Mar 2026 |
|
| Vanguard Capital Management | 291k | $2.2M | 100% | Mar 2026 |
|
| Rangeley Capital | 243k | $1.8M | 183% | Mar 2026 |
|
| Affinity Asset Advisors | 229k | $1.7M | 0% | Mar 2026 |
|
| Susquehanna International | 202k | $1.5M | 70% | Mar 2026 |
|
| Renaissance Technologies | 188k | $1.4M | 44% | Mar 2026 |
|
| Acadian Asset Management | 152k | $1.1M | 21% | Mar 2026 |
|
| Millennium Management | 142k | $1.1M | 100% | Mar 2026 |
|
| Peapod Lane Capital | 127k | $925k | 0% | Mar 2026 |
|
| Ikarian Capital | 102k | $758k | 0% | Mar 2026 |
|
| BlackRock | 100k | $742k | 1% | Mar 2026 |
|
| ADAR1 Capital Management | 82k | $608k | -30% | Mar 2026 |
|
| Groupe la Francaise | 80k | $597k | 100% | Mar 2026 |
|
| Aldebaran Capital | 80k | $596k | 0% | Mar 2026 |
|
| Citadel Advisors | 75k | $558k | 100% | Mar 2026 |
|
| Geode Capital Management | 61k | $453k | -11% | Mar 2026 |
|
| Equitec Proprietary Markets | 58k | $427k | 100% | Mar 2026 |
|
| Credit Industriel Et Commercial | 54k | $398k | 100% | Mar 2026 |
|
| Torno Capital | 49k | $360k | 142% | Mar 2026 |
|
| Vanguard Fiduciary Trust | 41k | $306k | 100% | Mar 2026 |
|
| Dimensional Fund Advisors | 30k | $225k | 14% | Mar 2026 |
|
| Rbf Capital | 28k | $209k | 0% | Mar 2026 |
|
| State Street Corporation | 27k | $201k | 0% | Mar 2026 |
|
| Yakira Capital Management | 24k | $178k | 100% | Mar 2026 |
|
| Vazirani Asset Management | 22k | $163k | -55% | Mar 2026 |
|
| Jane Street | 21k | $159k | 100% | Mar 2026 |
|
| XTX Topco | 20k | $145k | 100% | Mar 2026 |
|
| Boothbay Fund Management | 16k | $120k | 0% | Mar 2026 |
|
| Northern Trust | 14k | $102k | 0% | Mar 2026 |
|
| FMR | 10k | $76k | 4808% | Mar 2026 |
|
| Wells Fargo & Company | 5.8k | $43k | -1% | Mar 2026 |
|
| Morgan Stanley | 4.3k | $32k | -25% | Mar 2026 |
|
| Goss Wealth Management | 2.2k | $16k | 100% | Mar 2026 |
|
| Vanguard Global Advisers | 1.7k | $13k | 100% | Mar 2026 |
|
| Royal Bank of Canada | 322.00 | $2.0k | 100% | Mar 2026 |
|
| Caitong International Asset Management | 308.00 | $2.3k | 100% | Mar 2026 |
|
| Tower Research Capital | 262.00 | $1.9k | -54% | Mar 2026 |
|
| Bnp Paribas Arbitrage, Snc | 89.00 | $659.997300 | 0% | Mar 2026 |
|
| Hanson McClain Advisors | 50.00 | $371.000000 | 0% | Mar 2026 |
|
| UBS Group | 13.00 | $95.999800 | -68% | Mar 2026 |
|
| Barclays | 1.00 | $7.000000 | 0% | Mar 2026 |
|
Who sold out of Kezar Life Sciences?
| Fund or Company Name | Date Sold | Shares Held | Valued At |
|---|---|---|---|
| Nantahala Capital Management | Dec 2025 | 277k | $1.7M |
| Stonepine Capital Management | Dec 2025 | 156k | $982k |
| Springbok Capital Management | Dec 2025 | 53k | $333k |
| Bridgeway Capital Management | Dec 2025 | 52k | $325k |
| None | Dec 2025 | 34k | $212k |
| Nano Cap New Millennium Growth Fund | Dec 2025 | 25k | $157k |
| Two Sigma Investments | Dec 2025 | 11k | $71k |
| Advisor Group Holdings | Dec 2025 | 94.00 | $590.996800 |